← Leaderboards
Richard Edward Lee
Arietis
$36,742,506
Attributed
$48,695,343
Total exposure
20
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$48,695,343 · 20
By mechanism
R01$43,126,917 · 12
P01$3,403,024 · 2
R21$876,401 · 2
T32$874,649 · 1
K22$264,852 · 1
R03$143,000 · 1
Top collaborators
- Michael Lafleur11 shared
- Richard Gerald Brennan5 shared
- Simon L Dove5 shared
- Kim Lewis5 shared
- Maria Schumacher5 shared
- Stephen W White4 shared
- Charles O Rock2 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoDesignStructureResistanceBaseCellsInfectionLeadDrug KineticsPharmaceutical PreparationsPathogenAntibioticsGenerationsAnalogPropertyIn VitroDrug DesignBacteriaSeriesEnsureDrug ResistanceModificationDrug DevelopmentComplex
Grant awards (81)
Targeting NuoD for the treatment of H. pylori$844,980
R01 · FY2025 · AI · contact PI
Hybrid Antibiotics for Persistent Infections$832,827
R01 · FY2025 · AI · contact PI
Molecular elucidation of the Francisella tularensis virulence mechanism$798,912
R01 · FY2025 · AI
Advancing Pantothenate Kinase Activation Therapy$735,373
R01 · FY2025 · NS · contact PI
Training in the Design and Development of Infectious Disease Therapeutics$255,408
T32 · FY2025 · AI · contact PI
Targeting NuoD for the treatment of H. pylori$844,980
R01 · FY2024 · AI · contact PI
Hybrid Antibiotics for Persistent Infections$842,568
R01 · FY2024 · AI · contact PI
Molecular elucidation of the Francisella tularensis virulence mechanism$798,912
R01 · FY2024 · AI
Spectinomycin analogs for NTM infections$781,206
R01 · FY2024 · AI · contact PI
Training in the Design and Development of Infectious Disease Therapeutics$226,658
T32 · FY2024 · AI · contact PI
Development of ureadepsipetides for drug-resistant infections$1,186,918
R01 · FY2023 · AI
Targeting NuoD for the treatment of H. pylori$865,480
R01 · FY2023 · AI · contact PI
Hybrid Antibiotics for Persistent Infections$860,889
R01 · FY2023 · AI · contact PI
Molecular elucidation of the Francisella tularensis virulence mechanism$798,912
R01 · FY2023 · AI
Spectinomycin analogs for NTM infections$784,246
R01 · FY2023 · AI · contact PI
Training in the Design and Development of Infectious Disease Therapeutics$169,344
T32 · FY2023 · AI · contact PI
Development of ureadepsipetides for drug-resistant infections$1,200,871
R01 · FY2022 · AI
Spectinomycin analogs for NTM infections$829,725
R01 · FY2022 · AI · contact PI
Molecular elucidation of the Francisella tularensis virulence mechanism$797,142
R01 · FY2022 · AI
Development of Novel Proteins Synthesis Inhibitors for MDR Tuberculosis$747,745
R01 · FY2022 · AI · contact PI
Training in the Design and Development of Infectious Disease Therapeutics$223,239
T32 · FY2022 · AI · contact PI
Development of ureadepsipetides for drug-resistant infections$1,209,617
R01 · FY2021 · AI
Molecular elucidation of the Francisella tularensis virulence mechanism$855,904
R01 · FY2021 · AI
Spectinomycin analogs for NTM infections$833,842
R01 · FY2021 · AI · contact PI
Development of Novel Proteins Synthesis Inhibitors for MDR Tuberculosis$778,890
R01 · FY2021 · AI · contact PI
Development of ureadepsipetides for drug-resistant infections$1,235,145
R01 · FY2020 · AI
Spectinomycin analogs for NTM infections$877,232
R01 · FY2020 · AI · contact PI
Development of Novel Proteins Synthesis Inhibitors for MDR Tuberculosis$811,999
R01 · FY2020 · AI · contact PI
Development of ureadepsipetides for drug-resistant infections$1,529,042
R01 · FY2019 · AI
Development of Novel Proteins Synthesis Inhibitors for MDR Tuberculosis$798,307
R01 · FY2019 · AI · contact PI
Development of Novel Proteins Synthesis Inhibitors for MDR Tuberculosis$856,731
R01 · FY2018 · AI · contact PI
Developing therapeutics to treat chronic infections$755,183
R01 · FY2018 · AI · contact PI
Development of Aminospectinomycins for Biodefense$691,964
R01 · FY2018 · AI · contact PI
New Antibacterial Discovery and Development Gordon Research Conference$6,500
R13 · FY2018 · AI · contact PI
Developing therapeutics to treat chronic infections$749,804
R01 · FY2017 · AI · contact PI
Development of Aminospectinomycins for Biodefense$691,963
R01 · FY2017 · AI · contact PI
Developing therapeutics to treat chronic infections$758,554
R01 · FY2016 · AI · contact PI
Development of Aminospectinomycins for Biodefense$691,963
R01 · FY2016 · AI · contact PI
Developing therapeutics to treat chronic infections$758,554
R01 · FY2015 · AI · contact PI
Development of Aminospectinomycins for Biodefense$691,963
R01 · FY2015 · AI · contact PI
Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential - r$387,209
R01 · FY2015 · AI
Development of novel proteins synthesis inhibitors for MDR tuberculosis$1,013,892
R01 · FY2014 · AI · contact PI
Developing therapeutics to treat chronic infections$746,404
R01 · FY2014 · AI · contact PI
Development of Aminospectinomycins for Biodefense$691,964
R01 · FY2014 · AI · contact PI
Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential - r$387,209
R01 · FY2014 · AI
Development of novel proteins synthesis inhibitors for MDR tuberculosis$936,466
R01 · FY2013 · AI · contact PI
Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential - r$363,977
R01 · FY2013 · AI
Development of novel proteins synthesis inhibitors for MDR tuberculosis$945,212
R01 · FY2012 · AI · contact PI
Inhibitors of latent M. tuberculosis$613,591
R01 · FY2012 · AI · contact PI
Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential - r$387,209
R01 · FY2012 · AI
Development of novel proteins synthesis inhibitors for MDR tuberculosis$940,979
R01 · FY2011 · AI · contact PI
Inhibitors of latent M. tuberculosis$674,231
R01 · FY2011 · AI · contact PI
Development of novel proteins synthesis inhibitors for MDR tuberculosis$1,034,057
R01 · FY2010 · AI · contact PI
Targeting the PlsX/Y pathway for novel antimicrobials$539,478
R01 · FY2010 · AI · contact PI
Inhibitors of latent M. tuberculosis$528,883
R01 · FY2010 · AI · contact PI
Targeting the PlsX/Y pathway for novel antimicrobials$544,103
R01 · FY2009 · AI · contact PI
Inhibitors of latent M. tuberculosis$351,546
R01 · FY2009 · AI · contact PI
Regulation of Vascular Redox State by Thioredoxin$349,409
P01 · FY2009 · HL · contact PI
Lipids of mycobacteria$252,000
R21 · FY2009 · AI · contact PI
Inhibitors of latent M. tuberculosis$81,959
R01 · FY2009 · AI · contact PI
Regulation of Vascular Redox State by Thioredoxin$338,482
P01 · FY2008 · HL · contact PI
Development of Tuberculosis Cell Wall Inhibitors$333,668
P01 · FY2008 · AI · contact PI
Lipids of mycobacteria$183,958
R21 · FY2008 · AI · contact PI
Development of new furanyl anti-tuberculosis inhibitors$493,828
R01 · FY2007 · AI · contact PI
Regulation of Vascular Redox State by Thioredoxin$332,286
P01 · FY2007 · HL · contact PI
Development of Tuberculosis Cell Wall Inhibitors$323,203
P01 · FY2007 · AI · contact PI
Development of new furanyl anti-tuberculosis inhibitors$498,298
R01 · FY2006 · AI · contact PI
Regulation of Vascular Redox State by Thioredoxin$351,795
P01 · FY2006 · HL · contact PI
Development of TB Cell Wall Inhibitors$331,714
P01 · FY2006 · AI · contact PI
Development of new furanyl anti-tuberculosis inhibitors$419,298
R01 · FY2005 · AI
Regulation of Vascular Redox State by Thioredoxin$351,129
P01 · FY2005 · HL
Development of TB Cell Wall Inhibitors$322,834
P01 · FY2005 · AI
Development of new furanyl anti-tuberculosis inhibitors$418,781
R01 · FY2004 · AI
Development of TB Cell Wall Inhibitors$368,504
P01 · FY2004 · AI
Whole Cell NMR Studies of MYcobacteria$71,500
R03 · FY2004 · AI
Development of TB cell wall biogenesis inhibitors$218,578
R21 · FY2003 · AI
Whole Cell NMR Studies of MYcobacteria$71,500
R03 · FY2003 · AI
Development of TB cell wall biogenesis inhibitors$20,265
R21 · FY2003 · AI
Development of TB cell wall biogenesis inhibitors$201,600
R21 · FY2002 · AI
DRUG TARGETING M. TUBERCULOSIS ARABINOSYL TRANSFERASES$107,999
K22 · FY2001 · AI
DRUG TARGETING M. TUBERCULOSIS ARABINOSYL TRANSFERASES$156,853
K22 · FY2000 · AI